Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β2-agonists in South Korea
2019
AbstractObjectives: We aimed to assess the cost-utility of reslizumab for patients with severe eosinophilic asthma uncontrolled with high-dose inhaled corticosteroids and long-acting β2-agonists (I...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
4
Citations
NaN
KQI